Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis

We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (P < 0.001), higher WBC (P = 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (P = 0.001), lower albumin (P = 0.018), higher serum uric acid (P = 0.001), higher LDH (P = 0.022), and the presence of CV risk factors (P = 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (P > 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49;P = 0.041) and venous thrombosis (HR = 7.08;P = 0.030) as well as with shorter overall survival (HR 2.08;P = 0.009). In multivariate analyses, CKD (HR = 1.8;P = 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7;P < 0.001); its effect being more pronounced in lower (HR = 3.56;P = 0.036) than higher DIPSS categories (HR = 2.07;P = 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.